Advertisement
BLFS vs NVCR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BLFS is a Hold and NVCR is a Hold.
BLFS's Indicator enters downward trend
The Aroon Indicator for BLFS entered a downward trend on September 21, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 199 similar instances where the Aroon Indicator formed such a pattern. In 182 of the 199 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for BLFS moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 20 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 69%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Moving Average Convergence Divergence Histogram (MACD) for BLFS turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 41 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLFS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
BLFS broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on BLFS as a result. In 75 of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
Following a +4.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where BLFS advanced for three days, in 235 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. BLFS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 56 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.497) is normal, around the industry mean (4.821). P/E Ratio (32.175) is within average values for comparable stocks, (36.081). BLFS's Projected Growth (PEG Ratio) (15.094) is slightly higher than the industry average of (4.456). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. P/S Ratio (16.779) is also within normal values, averaging (56.074).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
NVCR in -5.98% downward trend, sliding for three consecutive days on October 14, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NVCR declined for three days, in 312 of 352 cases, the price declined further within the following month. The odds of a continued downward trend are 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVCR as a result. In 66 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The 10-day moving average for NVCR crossed bearishly below the 50-day moving average on September 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 68%.
The Aroon Indicator for NVCR entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NVCR's RSI Indicator exited the oversold zone, 26 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVCR advanced for three days, in 207 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
NVCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. NVCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.846) is normal, around the industry mean (2.949). P/E Ratio (-10.823) is within average values for comparable stocks, (2.438). Projected Growth (PEG Ratio) (40.950) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (2.634) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
BLFS | NVCR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 98 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 56 | 98 | |
PRICE GROWTH RATING 1..100 | 36 | 60 | |
P/E GROWTH RATING 1..100 | 50 | 26 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVCR's Valuation (98) in the Medical Specialties industry is in the same range as BLFS (99). This means that NVCR’s stock grew similarly to BLFS’s over the last 12 months.
NVCR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BLFS (100). This means that NVCR’s stock grew similarly to BLFS’s over the last 12 months.
BLFS's SMR Rating (56) in the Medical Specialties industry is somewhat better than the same rating for NVCR (98). This means that BLFS’s stock grew somewhat faster than NVCR’s over the last 12 months.
BLFS's Price Growth Rating (36) in the Medical Specialties industry is in the same range as NVCR (60). This means that BLFS’s stock grew similarly to NVCR’s over the last 12 months.
NVCR's P/E Growth Rating (26) in the Medical Specialties industry is in the same range as BLFS (50). This means that NVCR’s stock grew similarly to BLFS’s over the last 12 months.
| BLFS | NVCR | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 69% | 3 days ago 74% |
| Stochastic ODDS (%) | 3 days ago 77% | 3 days ago 73% |
| Momentum ODDS (%) | 3 days ago 70% | 3 days ago 84% |
| MACD ODDS (%) | 3 days ago 79% | N/A |
| TrendWeek ODDS (%) | 3 days ago 78% | 3 days ago 84% |
| TrendMonth ODDS (%) | 3 days ago 83% | 3 days ago 82% |
| Advances ODDS (%) | 14 days ago 77% | 7 days ago 75% |
| Declines ODDS (%) | 18 days ago 83% | 5 days ago 89% |
| BollingerBands ODDS (%) | 3 days ago 76% | 3 days ago 76% |
| Aroon ODDS (%) | 3 days ago 90% | 3 days ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BLFS’s FA Score shows that 0 FA rating(s) are green while NVCR’s FA Score has 1 green FA rating(s).
- BLFS’s FA Score: 0 green, 5 red.
- NVCR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BLFS’s TA Score shows that 2 TA indicator(s) are bullish while NVCR’s TA Score has 4 bullish TA indicator(s).
- BLFS’s TA Score: 2 bullish, 6 bearish.
- NVCR’s TA Score: 4 bullish, 4 bearish.
Price Growth
BLFS (@Pharmaceuticals: Other) experienced а 0.00% price change this week, while NVCR (@Medical/Nursing Services) price change was -3.50% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.71%. For the same industry, the average monthly price growth was -3.86%, and the average quarterly price growth was +3.30%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -6.10%. For the same industry, the average monthly price growth was -8.07%, and the average quarterly price growth was -16.10%.
Reported Earning Dates
BLFS is expected to report earnings on Nov 05, 2026.
NVCR is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-1.71% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-6.10% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement